Cardiac Dimensions®,
Inc. is an early stage, venture-backed company developing a minimally
invasive implantable product to treat mitral valve regurgitation
associated with congestive heart failure (CHF). This percutaneous
approach to annuloplasty is accomplished by implanting a device
in the great cardiac vein / coronary sinus via a catheter-based
delivery system. The implant is designed to reshape the mitral annulus
that surrounds the valve and reduce the
mitral regurgitation.
More than 21 million people worldwide suffer
from CHF, with more than 5 million cases in the U.S., and the number
is growing rapidly. The development of mitral valve regurgitation
is common in these patients and contributes significantly to the
morbidity and mortality of people with CHF. |